CAS Number: 842133-18-0
Therapeutic Category
Anti-Diabetic
API Technology
Synthetic
Dose Form
Oral Solids
Available Regulatory Filing
USA
Tunisia
Europe
China
Brazil
Iran
Innovator Brand (USA)
INVOKANA
Mechanism of Action
Sodium-glucose co-transporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG), and thereby increases urinary glucose excretion (UGE).
Indication
INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus